{"entity":{"id":"sheba","kind":"institution","name":"Sheba Medical Center","aka":["Chaim Sheba Medical Center","Tel HaShomer","Sheba Cancer Center"],"tldr":"Israel's largest hospital, whose cancer centre led the POLO trial of olaparib in pancreatic cancer and runs one of the world's few TIL therapy programmes.","summary":"Sheba Medical Center at Tel HaShomer describes itself as the largest hospital in Israel and hosts the Jusidman Cancer Center. Talia Golan led the POLO trial that established maintenance olaparib for germline BRCA-mutated pancreatic cancer, the Ella Lemelbaum Institute for Immuno-Oncology under Jacob Schachter, Michal Besser and Gal Markel has treated melanoma patients with tumour-infiltrating lymphocytes since 2006, and the haematology division runs point-of-care CAR-T manufacturing. Sheba's ARC innovation centre and its large breast, gastrointestinal, thoracic and paediatric oncology services make it Israel's most active oncology trial site, and its Sackler-affiliated researchers publish widely on precision oncology.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Sheba_Medical_Center","links":[{"label":"Homepage","url":"https://www.shebaonline.org"},{"label":"Cancer Center","url":"https://www.shebaonline.org/departments/cancer-center/"}],"tags":[],"related":[],"cancers":["pancreatic","melanoma","breast-hr-positive","dlbcl"],"sections":["targeted-therapy","cell-therapy"],"technologies":["parp-inhibitor","til-therapy","car-t","checkpoint-inhibitor"],"targets":["brca","parp"],"drugs":["olaparib"],"companies":["astrazeneca"],"institutions":["tel-aviv-university","israel-national-cancer-registry"],"pathways":[],"terms":[],"trials":[],"people":["yitshak-kreiss","talia-golan","jacob-schachter","michal-besser","eitan-friedman"],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":["paper-besser-til-melanoma-intent-to-treat-ccr-2013"],"journals":[],"dependsOn":[],"notes":[],"city":"Ramat Gan","country":"IL","lat":32.045,"lng":34.842,"institutionType":"hospital","website":"https://www.shebaonline.org","university":"Tel Aviv University","programs":["POLO trial and BRCA-mutated pancreatic cancer","TIL therapy (Ella Lemelbaum Institute)","CAR-T manufacturing","ARC innovation centre","Paediatric oncology"]},"route":"/institutions/sheba/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"institution":[{"id":"rabin-davidoff-center","kind":"institution","name":"Davidoff Cancer Center, Rabin Medical Center","route":"/institutions/rabin-davidoff-center/"},{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","route":"/institutions/hadassah/"},{"id":"israel-national-cancer-registry","kind":"institution","name":"Israel National Cancer Registry","route":"/institutions/israel-national-cancer-registry/"},{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","route":"/institutions/rambam/"},{"id":"soroka-medical-center","kind":"institution","name":"Soroka University Medical Center","route":"/institutions/soroka-medical-center/"},{"id":"tel-aviv-sourasky","kind":"institution","name":"Tel Aviv Sourasky Medical Center","route":"/institutions/tel-aviv-sourasky/"},{"id":"tel-aviv-university","kind":"institution","name":"Tel Aviv University","route":"/institutions/tel-aviv-university/"},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/"}],"person":[{"id":"eitan-friedman","kind":"person","name":"Eitan Friedman","route":"/people/eitan-friedman/"},{"id":"gal-markel","kind":"person","name":"Gal Markel","route":"/people/gal-markel/"},{"id":"jacob-schachter","kind":"person","name":"Jacob Schachter","route":"/people/jacob-schachter/"},{"id":"michal-besser","kind":"person","name":"Michal Besser","route":"/people/michal-besser/"},{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/"},{"id":"yitshak-kreiss","kind":"person","name":"Yitshak Kreiss","route":"/people/yitshak-kreiss/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"paper":[{"id":"paper-besser-til-melanoma-intent-to-treat-ccr-2013","kind":"paper","name":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","route":"/key-papers/paper-besser-til-melanoma-intent-to-treat-ccr-2013/"},{"id":"paper-golan-brca-pancreatic-platinum-survival-bjc-2014","kind":"paper","name":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","route":"/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/"},{"id":"paper-worthington-precede-early-detection-biomarkers-ijc-2026","kind":"paper","name":"Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium","route":"/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/"},{"id":"paper-gabai-kapara-population-brca-screening-pnas-2014","kind":"paper","name":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","route":"/key-papers/paper-gabai-kapara-population-brca-screening-pnas-2014/"}],"trial":[{"id":"winther","kind":"trial","name":"WINTHER","route":"/trials/winther/"}]}}